Pfizer’s purchase of migraine medication maker Biohaven Pharmaceutical represents a commitment to expand the reach of its calcitonin gene-related peptide (CGRP) franchise, CEO Vlad Coric told CNBC’s Jim Cramer on Tuesday. “There are still over 300,000 physicians in the US who write for the older triptans and have not yet written for one oral CGRP,” […]
